Incyte Genomics Inc (INCY) — 分析摘要
Incyte Genomics Inc（INCY）的市值为25.21十亿美元，最近一年的营收同比增长了+21.2%。净利润率为25.0%。当前市盈率为17.6倍。
核心要点
- 营收同比变化+21.2%
- 净利润率25.0%
- 市盈率17.6倍
与SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH板块的其他公司相比，INCY的营收增长为+21.2%，市盈率为17.6倍。
Incyte Genomics Inc (INCY)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
毛利率为 92.5% — 请核实：除纯软件/IP外极少有企业维持 >90% 毛利率
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
行业
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
员工人数
2,844
总部
WILMINGTON, DE
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。